肾移植受者中预存与新生供者特异性抗体所致抗体介导排斥反应的比较
该研究基于北美与欧洲7个中心的771例肾活检标本,系统评估205例抗体介导排斥反应(ABMR)患者,其中预存DSA与新生DSA各占50%。新生DSA组蛋白尿更多、移植肾小球病变更重,但肾小球炎更轻,且IFNγ诱导性、NK细胞和T细胞转录本表达增加,而AKI转录本表达减少。预存DSA组8年移植物存活率显著优于新生DSA组(63% vs 34%,P<0.001)。
要点
- 新生DSA组8年移植物存活率显著低于预存DSA组(34% vs 63%,P<0.001)。
- 新生DSA是移植物丢失的独立危险因素(HR 1.82,95%CI 1.07-3.08,P=0.03)。
- 诊断时低eGFR(<30 ml/min/1.73 m²)和蛋白尿≥0.30 g/g是移植物丢失的独立预测因素。
核心结论
- 新生DSA所致ABMR的移植物存活率显著低于预存DSA所致ABMR,且新生DSA是移植物丢失的独立危险因素。
- 研究结果支持将肾脏移植给高度致敏患者,并应鼓励对患者进行新生DSA监测。
研究设计与样本
- 来自北美2个和欧洲5个中心的771例肾活检标本的队列研究。
- 对所有ABMR患者(n=205)进行临床和生物学参数、组织病理学、循环DSA及移植物基因表达的系统评估。
- 其中预存DSA患者103例(50%),新生DSA患者102例(50%)。
主要发现
- 与预存DSA组相比,新生DSA组蛋白尿增加、移植肾小球病变更重、肾小球炎更轻,但管周毛细血管炎和C4d沉积水平相似。
- 新生DSA组IFNγ诱导性、NK细胞和T细胞转录本表达增加,而AKI转录本表达减少。
- 预存DSA组移植物存活率优于新生DSA组(排斥后8年分别为63% vs 34%,P<0.001)。
- 多因素调整后,移植物丢失的主要独立决定因素包括:新生DSA(HR 1.82,95%CI 1.07-3.08,P=0.03)、诊断时低eGFR(<30 ml/min/1.73 m²;HR 3.27,95%CI 1.48-7.23,P<0.001)、尿蛋白/肌酐比值≥0.30 g/g(HR 2.44,95%CI 1.47-4.09,P<0.001)以及cg病变存在(HR 2.25,95%CI 1.34-3.79,P=0.002)。
临床怎么用
- 研究结果支持将肾脏移植给高度致敏患者,并应鼓励对患者进行新生DSA监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antibody-mediated rejection (ABMR) can occur in patients with preexisting anti-HLA donor-specific antibodies (DSA) or in patients who develop de novo DSA. However, how these processes compare in terms of allograft injury and outcome has not been addressed. From a cohort of 771 kidney biopsy specimens from two North American and five European centers, we performed a systematic assessment of clinical and biologic parameters, histopathology, circulating DSA, and allograft gene expression for all patients with ABMR (n=205). Overall, 103 (50%) patients had preexisting DSA and 102 (50%) had de novo DSA. Compared with patients with preexisting DSA ABMR, patients with de novo DSA ABMR displayed increased proteinuria, more transplant glomerulopathy lesions, and lower glomerulitis, but similar levels of peritubular capillaritis and C4d deposition. De novo DSA ABMR was characterized by increased expression of IFNγ-inducible, natural killer cell, and T cell transcripts, but less expression of AKI transcripts compared with preexisting DSA ABMR. The preexisting DSA ABMR had superior graft survival compared with the de novo DSA ABMR (63% versus 34% at 8 years after rejection, respectively; P<0.001). After adjusting for clinical, histologic, and immunologic characteristics and treatment, we identified de novo DSA ABMR (hazard ratio [HR], 1.82 compared with preexisting DSA ABMR; 95% confidence interval [95% CI], 1.07 to 3.08; P=0.03); low eGFR (<30 ml/min per 1.73 m2) at diagnosis (HR, 3.27; 95% CI, 1.48 to 7.23; P<0.001); ≥0.30 g/g urine protein-to-creatinine ratio (HR, 2.44; 95% CI, 1.47 to 4.09; P<0.001); and presence of cg lesions (HR, 2.25; 95% CI, 1.34 to 3.79; P=0.002) as the main independent determinants of allograft loss. Our findings support the transplant of kidneys into highly sensitized patients and should encourage efforts to monitor patients for de novo DSA.
引用
- Aubert O, Loupy A, Hidalgo L, et al. Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients. J Am Soc Nephrol. 2017. PMID: 28255002. doi:10.1681/ASN.2016070797
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。